^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Squamous Cell Carcinoma

    Related cancers:
    24h
    TNK2 promotes the EMT proliferation and invasion of esophageal squamous cell carcinoma by enhancing FOXO1 through the AKT pathway. (PubMed, Int Immunopharmacol)
    Genipin targets TNK2 to inhibit the progression of ESCC. It provides new insights into the pathogenesis of ESCC and theoretical basis for positioning TNK2 gene as a potential therapeutic target.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • FOXO1 (Forkhead box O1) • TNK2 (Tyrosine Kinase Non Receptor 2)
    1d
    Circ_0001741 regulates proliferation and invasion in ESCC via the miR-194-5p/E2F3 axis. (PubMed, World J Surg Oncol)
    Our findings establish that circ_0001741 drives ESCC progression by modulating the miR-194-5p/E2F3 axis, underscoring its therapeutic potential for ESCC treatment.
    Journal
    |
    E2F3 (E2F transcription factor 3) • MIR194 (MicroRNA 194)
    |
    dactinomycin
    2d
    Biomarker testing for carcinomas of the upper gastrointestinal tract (PubMed, Pathologie (Heidelb))
    In addition to the quality guideline-compliant technical performance of the tests, the biological heterogeneity of many of these biomarkers is also a diagnostic and clinical challenge. The current article provides an overview of current biomarker testing in the context of current treatment options for cancer of the upper gastrointestinal tract.
    Journal • PD(L)-1 Biomarker • IO biomarker • Biomarker testings
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    2d
    New Gene Signature-Based Prognostic Model for Patients With VEGF-Overexpressing Esophageal Squamous Cell Carcinoma. (PubMed, Biomed Res Int)
    ESCC patients with FAT1, FGF3, FGF12, and FGF19 mutations; advanced M stage; and high neutrophil counts tended to have poorer prognoses. A model based on a four-gene signature effectively predicts the prognosis of ESCC patients.
    Journal • Gene Signature
    |
    VEGFA (Vascular endothelial growth factor A) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • FAT1 (FAT atypical cadherin 1)
    3d
    A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi)
    3d
    Platelet Indices and ApoA1 as Predictive Markers in Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study. (PubMed, J Inflamm Res)
    Baseline and preoperative blood parameters (MPV, PDW, P-LCR) and preoperative ApoA1 are valuable predictors of treatment response and prognosis in LA-ESCC. Nomograms incorporating these markers offer reliable prognostic insights for DFS.
    Retrospective data • Journal • IO biomarker
    |
    APOA1 (Apolipoprotein A-I)
    4d
    Identification of 2 Ubiquitin-Proteasome System-Related Subtypes in Esophageal Squamous Cell Carcinoma for Prognostic and Immunotherapeutic Response Prediction. (PubMed, J Immunother)
    Selumetinib, entinostat, and erlotinib were identified as candidate drugs for cluster 2, whereas tozasertib, alpelisib, and cediranib showed higher suitability for cluster 1. Ten potential biomarkers, 13 transcription factors, and 2 miRNAs were characterized. This study elucidates the role of UPS in ESCC progression and provides a framework for personalized treatment strategies.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8)
    |
    erlotinib • Koselugo (selumetinib) • Piqray (alpelisib) • Jingzhuda (entinostat) • Recentin (cediranib) • tozasertib (MK-0457)
    4d
    MIF-expressing tumor cells mediate immunotherapeutic resistance in esophageal squamous cell carcinoma. (PubMed, Theranostics)
    This disrupts GC reactions by competing with the CXCL12-CXCR4 signaling axis via MIF-CXCR4 interactions, thereby impairing B cell-mediated immunity. MIF+ tumor cells in GCs may be a biomarker for predicting immunotherapy resistance in ESCC.
    Journal • IO biomarker
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • MIF (Macrophage Migration Inhibitory Factor)
    6d
    Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=26, Recruiting, Shanghai Zhongshan Hospital
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • Enweida (envafolimab)
    7d
    SAFE ESO: Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma (clinicaltrials.gov)
    P2, N=95, Recruiting, University Hospital, Clermont-Ferrand | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr)
    7d
    Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov)
    P2, N=142, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    AiRuiLi (adebrelimab)